Stock Events

Stock Events

Summit Therapeutics 

$14.19
0
-$1.07-7.01% Today

Statistics

Day High
14.34
Day Low
14.14
52W High
-
52W Low
-
Volume
54,568
Avg. Volume
-
Mkt Cap
10.56B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MarExpected
Q3 2025
Next
-0.31
-0.23
-0.16
-0.08
Expected EPS
-0.080185
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-442.63MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SMMT.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a direct competitor in the cystic fibrosis market, where Summit Therapeutics is also aiming to make significant advancements.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences competes in the antiviral space, particularly in treatments for HIV, hepatitis B, and hepatitis C, areas where Summit Therapeutics has shown interest.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the area of infectious diseases and immunology, which overlaps with Summit's research interests.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is involved in developing therapies for infectious diseases, including antibiotics and antivirals, making it a competitor to Summit Therapeutics.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad portfolio that includes treatments for infectious diseases, directly competing with Summit Therapeutics' focus areas.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a diverse portfolio that includes treatments for infections, competing with Summit Therapeutics in the infectious disease space.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the area of infectious diseases, an area of focus for Summit Therapeutics.
Novartis
NVS
Mkt Cap237.61B
Novartis competes in multiple therapeutic areas, including those targeted by Summit Therapeutics, such as infectious diseases.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on innovative therapeutics in areas that could overlap with Summit Therapeutics' interests, including treatments for serious illnesses.
Biogen
BIIB
Mkt Cap22.63B
Biogen's focus on novel therapies for neurological and neurodegenerative diseases places it in competition with Summit Therapeutics' broader focus on innovative treatments.

About

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Show more...
CEO
Mr. Robert W. Duggan
Employees
159
Country
US
ISIN
US86627T1088

Listings

MX
MX
SMMT.MX
XNAS
US
SMMT
BOATS
BOATS
SMMT.BOATS

0 Comments

Share your thoughts

FAQ

What is Summit Therapeutics stock price today?▼
The current price of SMMT.BOATS is $14.19 USD — it has decreased by -7.01% in the past 24 hours. Watch Summit Therapeutics stock price performance more closely on the chart.
What is Summit Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Summit Therapeutics stocks are traded under the ticker SMMT.BOATS.
What is Summit Therapeutics market cap?▼
Today Summit Therapeutics has the market capitalization of 10.56B
When is the next Summit Therapeutics earnings date?▼
Summit Therapeutics is going to release the next earnings report on March 12, 2026.
What were Summit Therapeutics earnings last quarter?▼
SMMT.BOATS earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.17 USD resulting in a -82.3% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Summit Therapeutics revenue for the last year?▼
Summit Therapeutics revenue for the last year amounts to 0 USD.
What is Summit Therapeutics net income for the last year?▼
SMMT.BOATS net income for the last year is -442.63M USD.
How many employees does Summit Therapeutics have?▼
As of February 02, 2026, the company has 159 employees.
In which sector is Summit Therapeutics located?▼
Summit Therapeutics operates in the Health Care sector.
When did Summit Therapeutics complete a stock split?▼
Summit Therapeutics has not had any recent stock splits.
Where is Summit Therapeutics headquartered?▼
Summit Therapeutics is headquartered in Miami, US.